Clinical trial

Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients

NCT00000821

StatusCOMPLETED

Study typeINTERVENTIONAL

Start dateUnknown

PhasePHASE1

Study timeline

Registry last updated2021-11-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV Infectionsunresolved

Interventions

AldesleukinDRUG · verified · RxNorm: aldesleukin

Sponsors & collaborators

National Institute of Allergy and Infectious Diseases (NIAID)lead sponsor

Mapped research locations

BethesdaMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00000821 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.